Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Surgeon General
  • Cigna’s ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

TRENDING TOPICS:

  • Surgeon General
  • Cigna's ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, Nov 10 2020

Full Issue

Brazil Halts Sinovac Trial After 'Severe Adverse Event'

Brazilian media reported that one volunteer had died but that the death was unrelated to trials of China's Sinovac vaccine, the Wall Street Journal said. In other news: Another study has found that hydroxychloroquine doesn't help hospitalized COVID patients.

The Wall Street Journal: Brazil Suspends Trials Of China’s Sinovac Coronavirus Vaccine 

Brazil’s health regulator Anvisa said Monday it has suspended clinical trials of China’s Sinovac coronavirus vaccine, long expected to be one of the first to be approved in the country, following a “severe adverse event.” Anvisa said late Monday that the event occurred on Oct. 29, without giving further information or an explanation of why it took more than a week to communicate the problem. (Pearson, 11/10)

Stat: Drug Companies Deliver A Vote Of Confidence In Adaptive Trial For Covid-19

A novel clinical trial that uses artificial intelligence to rapidly compare Covid-19 treatments has attracted participation from two major drug companies, a key milestone in the effort to shake up the way trials are conducted. Amgen and the Japanese pharmaceutical company Eisai will become the first pharma companies to test their experimental therapies in REMAP-CAP, an adaptive clinical trial that seeks to rapidly evaluate potential Covid-19 treatments in patients around the world. (Ross, 11/10)

The Hill: NIH Study: Hydroxychloroquine Had No Benefit For Hospitalized COVID-19 Patients 

Hydroxychloroquine provides no benefit for hospitalized COVID-19 patients, a study from the National Institutes of Health (NIH) has officially concluded. The report was published in the Journal of the American Medical Association on Monday, though the NIH stopped the study in June on the recommendation of an independent data monitoring board. The study found that while hydroxychloroquine did not cause any additional harm, it didn't help patients either. (Weixel, 11/9)

Also —

Stat: STAT-Harris Poll: Most Won't Get A Covid-19 Vaccine Unless It Halves Risk

Six in 10 Americans said they are somewhat or very likely to get a Covid-19 vaccine if doing so would lower the risk of becoming infected by about half, according to a new survey from STAT and The Harris Poll. The poll also found that more Americans say they are likely to get a vaccine, practice social distancing, and wear a mask if they or someone they know has contracted Covid-19. (Silverman, 11/10)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF